Alkem issued with Form 483 by US FDA

By Gareth Macdonald

- Last updated on GMT

Related tags Food and drug administration

Alkem issued with Form 483 by US FDA
The US FDA has issued Indian API firm Alkem Laboratories Ltd. with a Form 483 after an inspection at is site in Ankleshwar, Gujarat.

The Form 483 – detailed in a filing on the Bombay Stock Exchange (BSE) today – lists three problems US Food and Drug Administration (FDA) investigators identified at the facility during an inspection this month.

Alkem said it is working on a response. The firm did not give details of the issues identified by the the US team.

The Form 483 comes a little over two months​ after Alkem's facility in finished dosage form plant in Daman passed an FDA inspection with no observations.

Alkem owns and operates 14 manufacturing facilities in India and two in the US. Its API plants are in Ankleshwar and Mandwa.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars